Clinical Trial Update: Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial BRIEF TB evaluating rifapentine-isoniazid for tuberculosis prevention has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• rifapentine + isoniazid (rifapentine; isoniazid)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Tuberculosis, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2018-12-06